Glaukos Co. (NYSE:GKOS) Director Sells $392,010.00 in Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Glaukos Price Performance

Glaukos stock traded down $0.24 during trading hours on Wednesday, hitting $125.50. 443,954 shares of the stock were exchanged, compared to its average volume of 585,500. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The stock has a market capitalization of $6.90 billion, a P/E ratio of -43.58 and a beta of 1.02. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60. The business’s 50-day moving average is $124.18 and its two-hundred day moving average is $109.64.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period in the prior year, the business earned ($0.55) earnings per share. Glaukos’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in Glaukos by 17.9% in the fourth quarter. Russell Investments Group Ltd. now owns 17,891 shares of the medical instruments supplier’s stock valued at $1,422,000 after buying an additional 2,715 shares during the period. Victory Capital Management Inc. lifted its holdings in Glaukos by 7.8% in the fourth quarter. Victory Capital Management Inc. now owns 19,763 shares of the medical instruments supplier’s stock valued at $1,571,000 after buying an additional 1,426 shares during the period. National Bank of Canada FI acquired a new position in Glaukos in the fourth quarter valued at approximately $46,000. Charles Schwab Investment Management Inc. lifted its holdings in Glaukos by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 392,240 shares of the medical instruments supplier’s stock valued at $31,179,000 after buying an additional 5,450 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Glaukos by 214.0% in the fourth quarter. BNP Paribas Financial Markets now owns 93,034 shares of the medical instruments supplier’s stock valued at $7,395,000 after buying an additional 63,403 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research upped their target price on shares of Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Truist Financial reissued a “buy” rating and issued a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $129.82.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.